Welcome to our dedicated page for Lumexa Imaging Holdings SEC filings (Ticker: LMRI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Lumexa Imaging Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Lumexa Imaging Holdings's regulatory disclosures and financial reporting.
BRODNAX BRETT reported acquisition or exercise transactions in this Form 4 filing.
Lumexa Imaging Holdings director Brett Brodnax received a grant of 19,358 restricted stock units (RSUs) of common stock. The award was made at no cash cost per unit and increases his direct holdings to 81,385 shares. The RSUs vest on the earlier of one year from the grant date or the next annual stockholder meeting, as long as he continues serving the company.
Lumexa Imaging Holdings, Inc. reported results of its 2026 Annual Meeting of Stockholders. Stockholders elected three Class I directors—Lee Cooper, Brian Regan and Caitlin Zulla—to serve until the 2029 annual meeting.
As of the April 13, 2026 record date, 96,110,039 common shares were entitled to vote. Lee Cooper received 87,523,628 votes for and 3,328,050 withheld, Brian Regan received 80,044,532 for and 10,807,146 withheld, and Caitlin Zulla received 87,156,663 for and 3,695,015 withheld, with 826,898 broker non-votes for each. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the year ending December 31, 2026 with 91,555,829 votes for, 66,858 against and 55,889 abstentions.
Lumexa Imaging Holdings director Brett Brodnax reported an open-market purchase of 35,000 shares of Common Stock at $7.25 per share. Following this transaction, he directly owns 62,027 Lumexa Imaging Holdings shares, according to the Form 4 insider filing.
Lumexa Imaging Holdings director-related trust buys shares
Cooper Family Trust, a revocable trust for which director Cooper Henry Lee and his spouse serve as co-trustees, purchased 30,000 shares of Lumexa Imaging Holdings, Inc. common stock in an open-market transaction at a weighted average price of $7.4371 per share on May 14, 2026.
Following the purchase, the trust holds 30,000 shares indirectly attributed to Lee. He disclaims beneficial ownership of these shares except to the extent of his pecuniary interest.
Lumexa Imaging Holdings reported Q1 2026 total revenues of $252.5M, up from $245.0M a year earlier, driven by outpatient and professional imaging services. Net income was $1.7M, compared with a net loss of $7.7M in Q1 2025, with basic and diluted EPS of $0.02 versus $(0.11).
Operating cash flow improved to $2.9M from a use of $14.0M, while cash and cash equivalents ended at $51.2M. Long-term debt remained significant at $816.97M (excluding current portion), largely from a senior secured term loan. Adjusted EBITDA was $51.2M, essentially flat year over year.
The company operated 189 outpatient imaging centers across 13 states as of March 31, 2026, including 103 consolidated centers and 86 joint-venture centers accounted for under the equity method. Commercial payors provided 57% of consolidated net patient service revenue, with Medicare and Medicaid contributing another 28%.
Lumexa Imaging Holdings, Inc. reported a first-quarter 2026 profit and reiterated its full-year 2026 guidance. Total revenues rose to $252.5M from $245.0M, driven by higher outpatient imaging volumes and a greater mix of advanced procedures.
Net income improved to $1.7M, or $0.02 per diluted share, compared with a net loss of $7.7M, or $(0.11) per share, a year earlier. Adjusted EBITDA was stable at $51.2M, while adjusted diluted earnings per share increased to $0.18 from $0.04. System-wide total procedures grew, with advanced procedures expanding faster than overall volumes, supporting management’s view of sustained, profitable growth.
Lumexa Imaging Holdings, Inc. is asking stockholders to elect three Class I directors—Lee Cooper, Brian Regan and CEO Caitlin Zulla—to terms running until the 2029 annual meeting, and to ratify PwC as independent auditor for the year ending December 31, 2026.
The 2026 annual meeting will be held virtually on June 10, 2026 at 8:30 a.m. Eastern Time via webcast at www.proxydocs.com/LMRI, with advance online registration required by June 5, 2026. Holders of the company’s 96,110,039 outstanding common shares as of April 13, 2026 may vote.
The proxy also details board structure, committee memberships and independence, director retainers and annual equity awards, and 2025 executive pay. CEO Caitlin Zulla received a $750,000 salary, a $3.5 million signing bonus, equity awards tied to stock-price hurdles and a 2025 bonus based on Adjusted EBITDA and strategic goals.
Lumexa Imaging Holdings, Inc. reported that on April 8, 2026 it held a meeting and site visit where it reiterated its previously disclosed full year 2026 guidance. The company stated this information is furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act unless specifically designated or incorporated by reference.
Lumexa Imaging Holdings, Inc. reports full-year 2025 results as a newly public, national diagnostic imaging platform. The company operated 188 outpatient centers across 13 states as of December 31, 2025, supported by roughly 102,000 referring physicians from more than 32,000 practices.
Consolidated revenue reached $1.023 billion for 2025, up 7.8% from 2024, while system-wide revenue, which includes unconsolidated joint ventures, also grew 8.2%. Lumexa recorded a 2025 net loss of $47.1 million but generated Adjusted EBITDA of $230.2 million, a 22.5% margin, reflecting scale and operating leverage.
During 2025 the company completed an IPO of 25,000,000 common shares, raising approximately $427 million in net proceeds. Advanced imaging, particularly MRI and CT, was a key driver, accounting for 52% of consolidated revenue and 63% of system-wide revenue. Management highlights strong patient satisfaction, expansive health system joint ventures, and growing use of third-party AI and teleradiology (Connexia) as core competitive strengths.